Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation
- PMID: 14729650
- DOI: 10.1158/0008-5472.can-03-1452
Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation
Abstract
Adult T-cell leukemia (ATL) caused by human T-cell leukemia virus type I (HTLV-I) is characterized by poor prognosis after chemotherapy. Recent clinical trials have indicated, however, that allogeneic but not autologous hematopoietic stem cell transplantation (HSCT) for ATL can yield better clinical outcomes. In the present study, we investigated cellular immune responses of ATL patients who obtained complete remission after nonmyeloablative allogeneic peripheral blood HSCT from HLA-identical sibling donors. In the culture of peripheral blood mononuclear cells (PBMCs) from a post-HSCT but not pre-HSCT ATL patient, CD8(+) CTLs proliferated vigorously in response to stimulation with autologous HTLV-I-infected T cells that had been established before HSCT in vitro. These CTLs contained a large number of monospecific CTL population directed to a HLA-A2-restricted HTLV-I Tax 11-19 epitope. The frequency of Tax 11-19-specific CD8+ CTLs in this patient markedly increased also in vivo after HSCT, as determined by staining with HLA-A2/Tax 11-19 tetramers. Similar clonal expansion of HTLV-I Tax-specific CTLs exclusively directed to a HLA-A24-restricted Tax 301-309 epitope was observed in the PBMCs from another ATL patient after HSCT from a HTLV-I-negative donor. Among four post-HSCT ATL patients tested, HTLV-I-specific CTLs were induced in the PBMC culture from three patients but not from the remaining one who had later recurrence of ATL. These observations suggested that reconstituted immunity against antigen presentation in ATL patients after HSCT resulted in strong and selective graft-versus-HTLV-I response, which might contribute to graft-versus-leukemia effects.
Similar articles
-
Long-term persistence of limited HTLV-I Tax-specific cytotoxic T cell clones in a patient with adult T cell leukemia/lymphoma after allogeneic stem cell transplantation.J Clin Immunol. 2012 Dec;32(6):1340-52. doi: 10.1007/s10875-012-9729-5. Epub 2012 Jul 5. J Clin Immunol. 2012. PMID: 22763862
-
Potential contribution of a novel Tax epitope-specific CD4+ T cells to graft-versus-Tax effect in adult T cell leukemia patients after allogeneic hematopoietic stem cell transplantation.J Immunol. 2013 Apr 15;190(8):4382-92. doi: 10.4049/jimmunol.1202971. Epub 2013 Mar 8. J Immunol. 2013. PMID: 23475215
-
Single-cell analysis of T-cell receptor repertoire of HTLV-1 Tax-specific cytotoxic T cells in allogeneic transplant recipients with adult T-cell leukemia/lymphoma.Cancer Res. 2010 Aug 1;70(15):6181-92. doi: 10.1158/0008-5472.CAN-10-0678. Epub 2010 Jul 20. Cancer Res. 2010. PMID: 20647322
-
Maintenance of long remission in adult T-cell leukemia by Tax-targeted vaccine: A hope for disease-preventive therapy.Cancer Sci. 2019 Mar;110(3):849-857. doi: 10.1111/cas.13948. Epub 2019 Feb 19. Cancer Sci. 2019. PMID: 30666755 Free PMC article. Review.
-
Impact of host immunity on HTLV-1 pathogenesis: potential of Tax-targeted immunotherapy against ATL.Retrovirology. 2019 Aug 22;16(1):23. doi: 10.1186/s12977-019-0484-z. Retrovirology. 2019. PMID: 31438973 Free PMC article. Review.
Cited by
-
Understanding the Immunopathology of HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: A Comprehensive Review.Biomolecules. 2023 Oct 19;13(10):1543. doi: 10.3390/biom13101543. Biomolecules. 2023. PMID: 37892225 Free PMC article. Review.
-
Viral, genetic, and immune factors in the oncogenesis of adult T-cell leukemia/lymphoma.Int J Hematol. 2023 Apr;117(4):504-511. doi: 10.1007/s12185-023-03547-5. Epub 2023 Jan 27. Int J Hematol. 2023. PMID: 36705848 Review.
-
AIM™ platform: A new immunotherapy approach for viral diseases.Front Med (Lausanne). 2022 Dec 23;9:1070529. doi: 10.3389/fmed.2022.1070529. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36619639 Free PMC article.
-
T cell receptor repertoire analysis in HTLV-1-associated diseases.Front Immunol. 2022 Sep 15;13:984274. doi: 10.3389/fimmu.2022.984274. eCollection 2022. Front Immunol. 2022. PMID: 36189294 Free PMC article. Review.
-
Live attenuated VZV vaccination induces antitumor immunity in ATLL patients.Cancer Immunol Immunother. 2023 Apr;72(4):929-944. doi: 10.1007/s00262-022-03301-6. Epub 2022 Oct 1. Cancer Immunol Immunother. 2023. PMID: 36181532 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous
